In partnership with global diagnostics company QIAGEN®, Ellume has developed two rapid COVID-19 tests: the QIAreach™ SARS-CoV-2 Antigen Test* for active infections and the QIAreach™ Anti-SARS-CoV-2 Total Test** for past infections.
The tests are run on the eHub platform, an easy-to-use and portable digital device that provides results in less than 15 minutes.
QIAreach™ Antigen and Antibody Tests: Fighting the COVID-19 Pandemic
The QIAreach™ Anti-SARS-CoV-2 Total Test, is a high-performance serological test which detects antibodies in people who have been exposed to SARS-CoV-2. The test received U.S. FDA Emergency Use Authorization (EUA) in May 2021*.
The QIAreach™ Anti-SARS-CoV-2 Antigen Test detects SARS-CoV-2 antigens in people with active infections. The test received U.S. FDA Emergency Use Authorization (EUA) in August 2021**.Learn More
QIAreach™ QuantiFERON®-TB: Fighting the tuberculosis epidemic
We are bringing the next generation of Latent Tuberculosis Infection diagnostics to those who need it most.
In partnership with QIAGEN®, we are advancing the way tuberculosis is diagnosed. Combining our technology with Qiagen’s market leading test, QuantiFERON®, we are taking testing out of the laboratory and into the community.
The QIAreach™ QuantiFERON®-TB test for tuberculosis (TB) infection, received CE marketing in October 2021 and is now accessible in high burden, low-resource countries and decentralized settings.